Pfizer more than doubles price of Covid-19 medication Paxlovid, shortages in poorer countries

Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase | CNN The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday. Meg Tirrell CNN

The list price, before insurance, will be $1,390 for a five-day course, Pfizer said in a statement. That’s 2.6 times higher than the $530-per-course price paid by the US government, which provided Paxlovid free to patients during the pandemic. The Wall Street Journal first reported the new price.

Pfizer noted that the list price “does not necessarily reflect the price a patient will pay” and said it’s working to secure health insurance arrangements that would come with low out-of-pocket costs to patients. The company also said it would offer assistance with copays for people who qualify, which could bring their out-of-pocket costs to nothing.

...

ALSO SEE: Shortage of Paxlovidin Lower and Middle Income Countries  During COVID-19 Emergency